XML 35 R21.htm IDEA: XBRL DOCUMENT v3.22.2.2
Restructuring
9 Months Ended
Sep. 30, 2022
Restructuring and Related Activities [Abstract]  
Restructuring Restructuring
In April 2022, the Board of Directors of the Company approved a comprehensive restructuring plan intended to reduce operating expenses. The Company intends to maintain targeted research efforts focused on in-vivo LVV gene therapy and to deprioritize direct investments in reduced toxicity conditioning and cryopreserved apheresis.
As part of the restructuring, the Company reduced its workforce by nearly 30% across the second and third quarters of 2022. The Company incurred approximately $4.9 million in costs to implement the restructuring, comprised primarily of severance payments and continuing health care coverage over the severance period. The restructuring actions associated with these charges commenced in April 2022, and were completed by September 30, 2022.
The following table summarizes the accrued liabilities activity recorded in connection with the restructuring as of September 30, 2022:
As of September 30, 2022
Beginning balance$— 
Total estimated expenses$6,639 
Expenses paid from inception through September 30, 2022$4,940 
Reversal of excess accrual through September 30, 2022$(1,699)
Remaining accrual at September 30, 2022$—